Feasibility study of Bismuth Subsalicylate (BSS) as an addition to standard of care for COVID-19 therapy

Yacyshyn, Mary Beth; Collins, James K.; Chua, Michelle J.; Siegwald, Angela; Yacyshyn, Sara; Briones-Pryor, Valerie; Yacyshyn, Bruce

doi:10.1016/j.curtheres.2022.100667

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 46 Other clinical data for BSS also confirmed the feasibility of BSS for COVID-19 co-therapy. 47 All these data from an enzyme level to clinical stage supported our conclusion that bismuth-based therapy holds a great potential to be further developed in terms of pan-spectrum anti-coronavirus drugs.…”

Section: Discussionsupporting

confidence: 69%

Mechanistic insights into bismuth(iii) inhibition of SARS-CoV-2 helicase

Wei,

Chan,

Zhou

et al. 2024

Chem. Sci.

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 69%

Mechanistic insights into bismuth(iii) inhibition of SARS-CoV-2 helicase

Wei,

Chan,

Zhou

et al. 2024

Chem. Sci.

View full text Add to dashboard Cite

show abstract

WITHDRAWN: COVID-19: Post infection implications in different age groups, mechanism, diagnosis, effective prevention, treatment, and recommendations

Raheem,

Rahim,

Gul

et al. 2024

Life Sciences

View full text Add to dashboard Cite

Bismuth subsalicylate as potential treatment for Covid-19 pneumonia: A case series report

Kahlenborn¹,

Severs

Nawab³

2022

Front. Drug. Discov.

View full text Add to dashboard Cite

Various literature cited suggests that bismuth may have usefulness against Covid-19 both in vitro and in vivo. During the course of caring for Covid-19 patients we administered bismuth subsalicylate to those who displayed diarrhea and/or gastric complaints. Using relatively conservative criteria, upon retrospective review, we noted marked improvement in oxygen requirements in most of the cases. This improvement was observed even when prior therapy with standard anti-Covid drugs had failed. Our overall impression is that these positive results support a detailed evaluation of bismuth as an adjunct treatment for the treatment of Covid-19.

show abstract

Feasibility study of Bismuth Subsalicylate (BSS) as an addition to standard of care for COVID-19 therapy

Cited by 3 publications

References 9 publications

Mechanistic insights into bismuth(iii) inhibition of SARS-CoV-2 helicase

Mechanistic insights into bismuth(iii) inhibition of SARS-CoV-2 helicase

WITHDRAWN: COVID-19: Post infection implications in different age groups, mechanism, diagnosis, effective prevention, treatment, and recommendations

Bismuth subsalicylate as potential treatment for Covid-19 pneumonia: A case series report

Contact Info

Product

Resources

About